Showing results (161-170 of 317) with videos related to

Sort By:
Pageof 32
Bone Marrow Transplantation|October 30, 2012
Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioningL J DeCook, M Thoma, T Huneke, et al.
Leukemia Research|January 13, 2006
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literatureA Pardanani, R P Ketterling, C-Y Li, et al.
Blood Neoplasia|October 28, 2025
Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosisAbdulraheem Yacoub, Haris Ali, Vikas Gupta, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2019
Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell TransplantAlexandra Higgins, Zaraq Khan, Charles C Coddington, et al.
Blood Cancer Journal|April 1, 2017
Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patientsL Saeed, M M Patnaik, K H Begna, et al.
JCO Precision Oncology|July 8, 2024
Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective StudyYael Kusne, Terra Lasho, Christy Finke, et al.
Nature Medicine|December 13, 1997
Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNAS S Soldan, R Berti, N Salem, et al.
Blood Advances|August 11, 2020
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic featuresGiacomo Coltro, Giada Rotunno, Lara Mannelli, et al.
Bone Marrow Transplantation|November 1, 2020
Risk of relapse in patients receiving azithromycin after allogeneic HSCTJade L Kutzke, Julianna A Merten, Jodi L Taraba, et al.
Oncotarget|December 8, 2017
Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabineRosalie M Sterner, Kimberly N Kremer, Aref Al-Kali, et al.
Pageof 32